ATNM

Actinium Pharmaceuticals Inc

0.8211

Aug 12 • 3:59 PM ET +0.0280 (3.53%)

0.8211

Aftermarket • 5:00 PM ET 0.0000 (0.00%)

Healthcare Biotechnology USA Nano AMEX

Peers: ATOS GRCE INMB LTRN QNTM RNXT VERU XLO OTLK TLPH

| Held by: VTI VXF IWC BUSM

Scroll to Statements

Index	-
Market Cap	25.82M
Enterprise Value	-9.31M
Income	11.31M
Sales	35.09M
Book/sh	0.96
Cash/sh	1.16
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	25
IPO	Jun 02, 2011

P/E	2.30
Forward P/E	-
PEG	-
P/S	0.74
P/B	0.85
P/C	0.71
P/FCF	-
EV/EBITDA	-0.88
EV/Sales	-0.27
Quick Ratio	4.08
Current Ratio	4.08
Debt/Eq	0.04
LT Debt/Eq	0.02
Option/Short	Yes / Yes

EPS (ttm)	0.36
EPS next Y	-0.72
EPS next Q	0.89
EPS this Y	111.01%
EPS next Y	-700.00%
EPS next 5Y	11.72%
EPS past 3/5Y	7.39% 9.91%
Sales past 3/5Y	-54.09% -
EPS Y/Y TTM	127.10%
Sales Y/Y TTM	11.11%
EPS Q/Q	502.90%
Sales Q/Q	-
Earnings	May 11
EPS/Sales Surpr.	20.00% -

Insider Own	0.60%
Insider Trans	0.00%
Inst Own	16.76%
Inst Trans	-0.98%
ROA	21.92%
ROE	45.86%
ROIC	36.60%
Gross Margin	96.97%
Oper. Margin	27.23%
Profit Margin	32.23%
SMA20	-2.35%
SMA50	-12.87%
SMA200	-30.98%
Trades

Shs Outstand	31.44M
Shs Float	31.25M
Short Float	2.52%
Short Ratio	6.65
Short Interest	0.79M
52W High	1.81 -54.53%
52W Low	0.74 11.70%
Volatility	5.48% 4.45%
ATR (14)	0.04
RSI (14)	42.84
Beta	0.02
Rel Volume	2.03
Avg Volume	118.32K
Volume	240,645

Perf Week	9.67%
Perf Month	-8.27%
Perf Quarter	-36.84%
Perf Half Y	-27.97%
Perf YTD	-39.63%
Perf Year	-45.62%
Perf 3Y	-87.13%
Perf 5Y	-87.17%
Perf 10Y	-98.38%
Recom	1.00
Target Price	6.50
Prev Close	0.79
Price	0.82
Change %	3.53%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-07-24	Downgrade	B. Riley Securities	Buy → Neutral	$16 → $2
May-14-24	Initiated	Stephens	Overweight	$25
Sep-06-23	Initiated	HSBC Securities	Buy	$11.60
Feb-21-23	Downgrade	William Blair	Outperform → Mkt Perform
Sep-08-22	Initiated	Cantor Fitzgerald	Overweight	$20
Aug-25-22	Initiated	B. Riley Securities	Buy	$16
Nov-05-20	Initiated	Alliance Global Partners	Buy	$25
Dec-06-17	Initiated	B. Riley FBR, Inc.	Buy	$2.75
Oct-23-17	Resumed	ROTH Capital	Buy	$6
Sep-14-17	Initiated	Maxim Group	Buy	$3
Aug-25-16	Initiated	ROTH Capital	Buy	$5
Feb-29-16	Initiated	H.C. Wainwright	Buy	$8
Oct-15-15	Initiated	FBR Capital	Outperform	$12
Oct-01-14	Initiated	MLV & Co	Buy	$16
Jul-22-14	Initiated	Canaccord Genuity	Buy	$16

Show Previous Ratings

Aug-07-26 05:07PM	Actinium: Q2 Earnings Snapshot (Associated Press)
Jun-03-26 08:00AM	Actinium Presents New ATNM-400 Data in KRAS and EGFR Mutant Models at SNMMI 2026 Supporting a Mutation-Agnostic Opportunity In Non-Small Cell Lung Cancer (PR Newswire)
07:25AM	Actinium Pharmaceuticals Oral Presentation at SNMMI 2026 Highlights ATNM-400 Overcoming Resistance to All Three Approved Androgen Receptor Inhibitors and Offers Flexible, Well-Tolerated Dosing in Prostate Cancer Models (PR Newswire)
Jun-01-26 08:00AM	Actinium Appoints Accomplished Oncology Expert Steffen Heeger MD, MSc as Chief Medical Officer to Drive Rejuvenated Pipeline Development (PR Newswire) -6.35%
07:00AM	Actinium Pharmaceuticals Presents New Radiochemistry Data at SNMMI 2026 Demonstrating That CAR Optimization Improves Tumor Targeting and Pharmacokinetics of Actinium-225 Radioconjugates (PR Newswire)
05:31PM	Loading…
May-29-26 05:31PM	Actinium Pharmaceuticals Receives Two Patent Allowances Spanning Its Actimab-A and Iomab-ACT Programs (PR Newswire) +9.57%
05:30PM	Actinium Pharmaceuticals to Present ATNM-400 Program Update at SNMMI 2026 Conference on May 31-June 2 and Provides NYSE American Listing Standards Notice (PR Newswire)
May-08-26 05:08PM	Actinium: Q1 Earnings Snapshot (Associated Press) +7.38%
May-06-26 08:00AM	Actinium Pharmaceuticals Announces Three SNMMI 2026 Presentations Highlighting Differentiated Profile of ATNM-400 Across Lung and Prostate Cancer and Radioconjugate Optimization (PR Newswire)
Apr-22-26 07:00AM	Actinium Pharmaceuticals, Inc. Announces Compelling Pan-Tumor Data for ATNM-400 Demonstrating Broad Efficacy Across Prostate, Lung, and Breast Cancer Models at the 2026 American Association of Cancer Research Annual Meeting (PR Newswire) -7.89%
07:00AM	Actinium Highlights Transcriptional Reprogramming as a Key Mechanism Underpinning Mutation-Agnostic Activity of Actimab-A in AML at the 2026 American Association of Cancer Research Annual Meeting (PR Newswire)
Apr-06-26 07:30AM	Actinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for ATNM-400 in Solid Tumors and Differentiated Mechanism for Actimab-A in AML to be Presented at 2026 AACR Annual Meeting (PR Newswire) +11.18%
Mar-30-26 06:27PM	Actinium: Q4 Earnings Snapshot (Associated Press)
Feb-17-26 07:42AM	Actinium Pharmaceuticals, Inc. to Present Two Abstracts at the 2026 AACR Annual Meeting (PR Newswire)
Dec-22-25 09:40AM	Are Medical Stocks Lagging Actinium Pharmaceuticals (ATNM) This Year? (Zacks) -5.33%
08:45AM	Loading…
Dec-12-25 08:45AM	Actinium Pharmaceuticals Presents New Preclinical Data Demonstrating Potent Anti-Tumor Activity of ATNM-400 Across Multiple Breast Cancer Subtypes Including Hormone Receptor-Positive, Triple-Negative, and Tamoxifen- and HER2 Therapy-Resistant Breast Cancer Models at SABCS 2025 (PR Newswire)
Dec-05-25 09:40AM	Are Medical Stocks Lagging Alpha Cognition Inc. (ACOG) This Year? (Zacks)
Dec-01-25 08:45AM	Actinium Pharmaceuticals Announces ATNM-400 Data Demonstrating Potent Efficacy in Triple-Negative Breast Cancer and Ability to Overcome Endocrine and HER2-Targeted Therapy Resistance Being Presented at the San Antonio Breast Cancer Symposium (PR Newswire)
Nov-19-25 09:41AM	Is Alpha Cognition Inc. (ACOG) Stock Outpacing Its Medical Peers This Year? (Zacks)
Nov-17-25 08:30AM	The Race for the Global Radiotherapy Cancer Market; Actinium Pharmaceuticals' (ATNM) Big Bet (Newsfile) +14.17%
Nov-14-25 05:01PM	Actinium: Q3 Earnings Snapshot (Associated Press Finance)
Nov-04-25 07:30AM	Actinium Pharmaceuticals, Inc. to Highlight ATNM-400 Data in Hormone-Resistant and HER2-Resistant Breast Cancer at the 2025 San Antonio Breast Cancer Symposium, Expanding Pan-Tumor Profile Across Three Solid Tumor Indications (PR Newswire)
Nov-03-25 08:30AM	Actinium Pharmaceuticals, Inc. to Participate in the Stephens Biotechnology Virtual Fireside Chat Conference (PR Newswire)
Oct-27-25 07:00AM	Actinium Announces Superior Anti-Tumor Activity of ATNM-400 in Lung Cancer Compared to the Leading First, Second and Third-Line Approved EGFR Mutant Therapies and Mechanistic Synergy with Osimertinib at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (PR Newswire) -8.38%
Oct-24-25 08:30AM	Actinium Pharmaceuticals Presents New Data Demonstrating Potent and Durable Efficacy of ATNM-400, a First-in-Class Multi-Tumor Actinium-225 Radiotherapy, at the 32nd Annual Prostate Cancer Foundation Scientific Retreat (PR Newswire) +16.78%
Oct-13-25 12:10PM	Actinium Pharmaceuticals to Unveil the Multi-Tumor Potential of ATNM-400, a First-in-Class Actinium-225 Radiotherapy, with Data in Non-Small Cell Lung Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (PR Newswire) +8.05%
08:30AM	Actinium to Present ATNM-400 Preclinical Data Highlighting Durable Tumor Control and Ability to Overcome Resistance to Standard-of-Care Prostate Cancer Therapies at the 32nd Annual Prostate Cancer Foundation Scientific Retreat (PR Newswire)
Sep-18-25 09:40AM	Is Armata Pharmaceuticals (ARMP) Stock Outpacing Its Medical Peers This Year? (Zacks)
Sep-02-25 09:40AM	Is Actinium Pharmaceuticals (ATNM) Stock Outpacing Its Medical Peers This Year? (Zacks)
Aug-08-25 05:15PM	Actinium: Q2 Earnings Snapshot (Associated Press Finance)
08:30AM	Loading…
Jul-31-25 08:30AM	Actinium Presents Data Supporting Paradigm Changing Potential of ATNM-400 in Prostate Cancer Demonstrating Its Superior Efficacy and Improved Survival in Treatment Resistant Tumor Models versus Pluvicto and ARPI Therapy, and Also Enhanced Efficacy in Combination with ARPI Therapy at the 4th Annual Targeted Radiopharmaceuticals Summit (PR Newswire)
Jul-02-25 10:05PM	Actinium Highlights ATNM 400 Progress at SNMMI Conference (Insider Monkey) +5.93%
Jun-23-25 11:30AM	Actinium Highlights Expanded Data Set for ATNM-400 in Prostate Cancer Demonstrating Superior Efficacy to Enzalutamide and Ability to Overcome Resistance to ARPI Therapy and PSMA-Ac-225/Lu-177 Labelled Radiotherapy at the Society of Nuclear Medicine & Molecular Imaging Annual Meeting (PR Newswire)
Jun-13-25 08:35AM	Life Sciences Investor Forum: Now Available for Online Viewing (GlobeNewswire) -6.29%
Jun-10-25 02:38PM	Life Sciences Investor Forum Agenda Announced for June 11th-12th (GlobeNewswire) -8.76%
May-20-25 05:45AM	Investors in Actinium Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before May 27, 2025 to Discuss Your Rights - ATNM (PR Newswire)
May-09-25 05:33PM	Actinium: Q1 Earnings Snapshot (Associated Press Finance)
May-06-25 08:45AM	Actinium Announces Enrollment of First Patient in the Iomab-ACT Commercial CAR-T Trial at the University of Texas Southwestern Medical Center (PR Newswire) -8.00%
May-02-25 05:45AM	Actinium Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ATNM (PR Newswire)
Apr-30-25 07:25AM	Lawsuit for Investors in shares of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) announced by the Shareholders Foundation (PR Newswire) +6.29%
Apr-28-25 08:30AM	Actinium Presents Data Showing ATNM-400 is More Efficacious than Pluvicto and is Highly Efficacious after Pluvicto Resistance in Prostate Cancer Tumor Models at the American Association for Cancer Research Annual Meeting (PR Newswire)
08:00AM	Actinium Highlights Mutation Agnostic Antileukemic Activity of Actimab-A Against FLT3, NPM1, KMT2A and TP53 Mutations in AML Models Demonstrating Backbone Potential for Acute Myeloid Leukemia Treatment at the American Association for Cancer Research Annual Meeting (PR Newswire)
Apr-18-25 12:50PM	Actinium Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before May 27, 2025 to Discuss Your Rights ATNM (GlobeNewswire)
Apr-14-25 10:15AM	With Young Adult Cancer on the Rise, New Therapies Spark Investor Buzz (PR Newswire)
Apr-10-25 12:24PM	Actinium Pharmaceuticals, Inc. Sued for Securities Law Violations Contact Levi & Korsinsky Before May 27, 2025 to Discuss Your Rights ATNM (GlobeNewswire) -8.73%
Apr-08-25 05:45AM	Actinium Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before May 27, 2025 to Discuss Your Rights - ATNM (PR Newswire)
Apr-07-25 01:40PM	Actinium Pharmaceuticals, Inc. Sued for Securities Law Violations Investors Should Contact Levi & Korsinsky Before May 27, 2025 to Discuss Your Rights ATNM (GlobeNewswire) -5.43%
Apr-04-25 05:45AM	Actinium Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before May 27, 2025 to Discuss Your Rights - ATNM (PR Newswire) -7.19%
Mar-27-25 08:45AM	Actinium Pharmaceuticals Announces ATNM-400 a Novel Non-PSMA Targeting First in Class Prostate Cancer Radiotherapy Leveraging Actinium-225 (PR Newswire)
07:30AM	Actinium Pharmaceuticals Provides Business Update After Presentation at Trump Mar-A-Lago Club Announcing Novel Non-PSMA Prostate Cancer Radiotherapy ATNM-400 and Outlining Revitalized Clinical Pipeline with 2025 Corporate Objectives (PR Newswire)
Mar-26-25 08:45AM	Actinium Pharmaceuticals to Present Business Update at Trump Mar-A-Lago Club Today (PR Newswire) +18.35%
Mar-25-25 06:00AM	Actinium Pharmaceuticals to Host KOL Investor Call at 8am ET Today to Highlight Revamped Clinical Programs and Expanded Market Opportunities Including Newly Initiated Actimab-A Solid Tumor Program (PR Newswire) +6.04%
Mar-24-25 04:15PM	Actinium Pharmaceuticals Announces Supply Agreement with Eckert & Ziegler for Ac-225 Radioisotope to Support Comprehensive Development Activities (PR Newswire)
Mar-20-25 08:00AM	Actinium Pharmaceuticals Announces Research Collaboration with Memorial Sloan Kettering to Support Further Clinical Expansion of Actimab-A's Backbone Therapy Strategy (PR Newswire) +16.53%
Mar-19-25 08:30AM	Actinium Pharmaceuticals to Host Investor KOL Call with Dr. Ehab Atallah of the Medical College of Wisconsin and Provide a Pipeline Update Highlighting Revamped Clinical Programs and Expanded Market Opportunities for Actimab-A and Iomab-ACT with Clinical Data in 2H:2025 (PR Newswire)
08:11AM	Actinium Pharmaceuticals launches clinical trial for Actimab-A in combination (TipRanks)
Mar-18-25 08:00AM	Actinium Pharmaceuticals Announces Clinical Trial Program in Solid Tumors Combining Actimab-A with PD-1 Checkpoint Inhibitors KEYTRUDA and OPDIVO (PR Newswire) -8.46%
Mar-17-25 08:50AM	Actinium Pharmaceuticals Announces Publication of Actimab-A + CLAG-M Trial Results in Patients with Relapsed or Refractory Acute Myeloid Leukemia in the Peer-Reviewed Journal Leukemia (PR Newswire) +5.69%
Mar-12-25 08:00AM	Actinium Pharmaceuticals to Participate at the 37th Annual Roth Conference (PR Newswire)
Mar-11-25 08:30AM	Actinium Pharmaceuticals Announces Initiation of Actimab-A Triplet Combination Frontline Trial Under NCI CRADA with Venetoclax and Taiho Oncology's Hypomethylating Agent ASTX-727 in Patients with Newly Diagnosed AML (PR Newswire)
Nov-18-24 08:00AM	Actinium Pharmaceuticals Highlights Antibody Radiation Conjugate Program Developments and Reports Financial Results for the Third Quarter 2024 (PR Newswire) -5.33%
Nov-14-24 07:02PM	Actinium: Q3 Earnings Snapshot (Associated Press Finance) -9.09%
Nov-04-24 07:30AM	Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors (PR Newswire)
Oct-18-24 12:00PM	All You Need to Know About Actinium (ATNM) Rating Upgrade to Strong Buy (Zacks) +5.81%
Sep-23-24 04:52AM	Actinium Pharmaceuticals reports data from Phase III trial of AML treatment (Clinical Trials Arena)
Sep-20-24 08:00AM	Actinium Pharmaceuticals Announces Publication of Results from the Phase 3 SIERRA Trial of Iomab-B in the Journal of Clinical Oncology (PR Newswire)
Sep-12-24 07:59AM	Transforming Cancer Therapy Stocks to Watch In The Oncology Sector (News Direct)
Aug-21-24 05:00AM	The Future of Medicine: Key Biotech Stocks to Watch (News Direct)
Aug-05-24 06:59PM	Actinium: Q2 Earnings Snapshot (Associated Press Finance) -59.81% +15.73%
07:00AM	Actinium Provides Regulatory Update on Planned BLA Filing and Future Plans for Iomab-B in the U.S. (PR Newswire)
Aug-01-24 08:00AM	Actinium Expands Patent Coverage Over Iomab-ACT, its Next-Generation Targeted Radiotherapy Conditioning Agent, for Gene Edited Stem Cell-Based Therapies for Non-Malignant Indications (PR Newswire)
Jul-25-24 08:45AM	Actinium Announces FDA Clearance of Iomab-ACT Targeted Conditioning IND Application for Sickle Cell Disease Patients Undergoing Bone Marrow Transplant in Collaboration with Columbia University (PR Newswire)
07:30AM	Actinium Pharmaceuticals to Present at the 3rd Annual Targeted Radiopharmaceuticals Summit US (PR Newswire)
Jul-11-24 02:23PM	3 Under-$10 Biotech Stocks That Could Make You Rich (InvestorPlace)
Jul-02-24 05:05PM	3 Clinical-Stage Biotech Stocks to Buy for Multibagger Returns (InvestorPlace)
Jun-20-24 09:40AM	Is Actinium Pharmaceuticals (ATNM) Outperforming Other Medical Stocks This Year? (Zacks)
Jun-18-24 08:45AM	Treatment of Blood Cancers - Biopharma Companies Building out their Pipeline of Solutions (Newsfile)
Jun-17-24 08:45AM	Biopharma Stocks Quest for Solutions for Acute Myeloid Leukemia (AML) (Newsfile)
08:00AM	Actinium Presents First Ever Data Demonstrating Actimab-A in Combination with Leading Menin Inhibitors Leads to Anti-Tumor Control and Potent Leukemic Cell Killing in Preclinical Acute Myeloid Leukemia Models at the 2024 EHA Congress (PR Newswire)
Jun-14-24 08:30AM	Actinium Highlights Oral Presentation at EHA 2024 Annual Congress Featuring Improved Outcomes in TP53 Positive Patients Receiving Iomab-B in the Phase 3 SIERRA Trial (PR Newswire)
Jun-11-24 08:30AM	Actinium Announces Results of Actimab-A + CLAG-M Combination Trial Highlighted in Oral Presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting (PR Newswire)
Jun-10-24 07:22PM	Under-$10 Picks: 3 Biotech Stocks That Can Double Before the End of 2024 (InvestorPlace)
08:30AM	Actinium Highlights Mutation Data from the Phase 3 SIERRA Trial of Iomab-B and Novel Linker Technology to Support Solid Tumor Antibody Radiation Conjugate Development at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting (PR Newswire)
Jun-07-24 07:30AM	Meme Mania Meets Medicine: 3 Biotech Stocks Primed to Soar (InvestorPlace)
May-15-24 08:30AM	Actinium to Host KOL Webinar to Discuss Iomab-ACT Commercial CAR T-Cell Therapy Trial Design, Objectives and Potential Market Opportunity (PR Newswire)
May-14-24 06:38PM	Actinium Announces Oral Presentation Detailing Improved Survival Outcomes in TP53 Positive Patients at the EHA 2024 Annual Congress and Presentation of Long-Term Efficacy Results in Older Patients Receiving an Iomab-B Led Bone Marrow Transplant in the Phase 3 SIERRA Trial (PR Newswire) +11.63%
10:24AM	3 Cheap Biotech Stocks to Buy Now: May 2024 (InvestorPlace)
07:46AM	Stephens Initiates Actinium Pharmaceuticals With Overweight Rating, $25 Price Target (MT Newswires)
May-13-24 08:30AM	Actinium Announces Multiple Abstracts Highlighting its Antibody Radiation Conjugates Iomab-B and Actimab-A and Novel Linker Technology for Solid Tumors Accepted for Presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting (PR Newswire)
May-07-24 08:00AM	Actinium Announces KOL Webinar to Highlight Recently Announced Iomab-ACT Trial with Leading FDA Approved Commercial CAR T-Cell Therapy Being Led by the University of Texas Southwestern (PR Newswire)
Apr-18-24 08:00AM	Actinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting (PR Newswire) -8.00%
Apr-15-24 12:54PM	Biotech on a Budget: 7 Stocks Under $10 With Huge Potential (InvestorPlace) -6.22%
Apr-01-24 08:00AM	Actinium Announces Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation at the 50th European Bone Marrow Transplant Annual Meeting (PR Newswire) +9.32%
Mar-26-24 07:18AM	Actinium Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell Therapy (PR Newswire) -6.34%
Mar-15-24 06:15AM	High-Risk, High-Reward: Little-Known Biotech Stock ATNM Could Soar on Breakthrough Cancer Treatment (InvestorPlace) +7.66%
Mar-11-24 07:30AM	Actinium Pharmaceuticals Launches Actinium-225 Focused Strategic Initiative to Leverage Proprietary Cyclotron Based Manufacturing Technology to Address Growing Market Demand (PR Newswire) -9.54%
Feb-26-24 07:30AM	Actinium Announces Iomab-B Markedly Increases Long Term Survival in Patients 65 Years or Older with Active Relapsed or Refractory AML in the Phase 3 SIERRA Trial at the 2024 Tandem Meetings \| Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® (PR Newswire) +21.14%
Feb-25-24 01:37PM	7 Biotech Penny Stocks on the Verge of Clinical Trial Victory (InvestorPlace)
Feb-23-24 07:30AM	Actinium Highlights Improved Survival with Iomab-B in TP53 Positive Relapsed Refractory Acute Myeloid Leukemia Patients in the SIERRA Trial and Other Presentations at the 2024 Tandem Meetings \| Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® (PR Newswire)
Jan-02-24 07:30AM	Actinium Announces Acceptance of Five Abstracts for Presentation at the 2024 Tandem Meetings \| Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® (PR Newswire)

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, discovery, and clinical development of targeted radiotherapies. It also develops and markets medicines for relapsed and refractory cancer patients. The company was founded in 2000 and is headquartered in New York, NY.

M.S.Mr. Sandesh C. Seth M.B.A.

Ph.D.Dr. Paul Diamond Esq.

Chief Business OfficerMs. Lynn M. Bodarky M.B.A.

M.Sc.Dr. Steffen Heeger M.D.

Vice President of Clinical Development BMT & Cellular TherapyDr. Madhuri Vusirikala M.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ATNM

Actinium Pharmaceuticals Inc

Upgrade your Finviz experience